Free Trial
→ A dividend every week of the year (From Market Savvy) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$97.40
-1.4%		$106.52
$81.97
▼
$135.13
$168.67B0.5911.29 million shs1.33 million shs
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$252.40
-2.3%		$265.71
$184.66
▼
$281.07
$608.03B0.217.94 million shs978,074 shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Abbott Laboratories stock logo
ABT
Abbott Laboratories
+0.57%-0.28%-8.86%+4.72%-25.82%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
+1.33%-2.71%-6.13%-0.09%+36.67%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$97.40
-1.4%		$106.52
$81.97
▼
$135.13
$168.67B0.5911.29 million shs1.33 million shs
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$252.40
-2.3%		$265.71
$184.66
▼
$281.07
$608.03B0.217.94 million shs978,074 shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Abbott Laboratories stock logo
ABT
Abbott Laboratories
+0.57%-0.28%-8.86%+4.72%-25.82%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
+1.33%-2.71%-6.13%-0.09%+36.67%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Abbott Laboratories stock logo
ABT
Abbott Laboratories
2.96
Moderate Buy$118.8822.06% Upside
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
2.80
Moderate Buy$276.229.44% Upside

Current Analyst Ratings Breakdown

Latest ABT and JNJ Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/7/2026
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOverweight$120.00
10/7/2026
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$287.00
10/6/2026
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$287.00 ➝ $290.00
10/5/2026
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$298.00 ➝ $303.00
10/2/2026
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Rothschild & Co Redburn logo
Rothschild & Co Redburn
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeNeutral ➝ Buy$119.00 ➝ $127.00
9/29/2026
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Bank of America Corporation logo
Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral$278.00
9/29/2026
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$270.00 ➝ $285.00
9/22/2026
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
9/18/2026
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold (C-) ➝ Hold (C)
9/10/2026
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
HSBC Holdings plc logo
HSBC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$290.00 ➝ $320.00
9/8/2026
Abbott Laboratories stock logo
ABT
Abbott Laboratories
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$135.00
(Data available from 10/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$44.33B3.80$6.94 per share14.04$30.35 per share3.21
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$94.19B6.46$13.98 per share18.05$33.85 per share7.46
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$6.52B$3.0931.5416.021.8211.65%17.69%9.44%10/21/2026 (Estimated)
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$26.80B$8.6329.2419.972.5021.48%32.42%13.35%10/13/2026 (Estimated)

Latest ABT and JNJ Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
10/21/2026Q3 2026
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$1.42N/AN/AN/A$12.99 billionN/A
10/13/2026Q3 2026
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$2.67N/AN/AN/A$25.38 billionN/A
7/16/2026Q2 2026
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$1.28$1.31+$0.03$0.53$12.52 billion$12.59 billion
7/15/2026Q2 2026
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$2.84$2.90+$0.06$2.27$25.06 billion$25.31 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$2.522.59%+10.39%81.55%54 Years
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$5.362.12%+5.25%62.11%64 Years

Latest ABT and JNJ Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
9/17/2026
Abbott Laboratories stock logo
ABT
Abbott Laboratories
quarterly$0.632.47%10/15/202610/15/202611/16/2026
7/15/2026
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
quarterly$1.341.96%8/25/20268/25/20269/8/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Abbott Laboratories stock logo
ABT
Abbott Laboratories
0.57
1.38
0.97
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.44
1.09
0.81

Institutional Ownership

CompanyInstitutional Ownership
Abbott Laboratories stock logo
ABT
Abbott Laboratories
75.18%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
69.55%

Insider Ownership

CompanyInsider Ownership
Abbott Laboratories stock logo
ABT
Abbott Laboratories
0.46%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.16%
CompanyEmployeesShares OutstandingFree FloatOptionable
Abbott Laboratories stock logo
ABT
Abbott Laboratories
115,0001.73 billion1.72 billionOptionable
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
138,2002.41 billion2.41 billionOptionable

Recent News About These Companies

Prediction: Johnson & Johnson Will Be a Faster-Growing Company by 2030 Than Most Investors Expect
 |  fool.comhttps://www.fool.com/investing/2026/10/08/prediction-johnson-johnson-will-be-a-faster-growin/?source=marketbeat&utm_source=marketbeat&utm_medium=feed&utm_campaign=article&referring_guid=0b81ba35-dda6-43b8-b956-7a79fd692b76
Johnson & Johnson (JNJ) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates
 |  zacks.comhttps://www.zacks.com/stock/news/3002686/johnson-johnson-jnj-q3-earnings-preview-what-you-should-know-beyond-the-headline-estimates?cid=cs-stocknewsapi-ft-fundamental_analysis|nfm_preview-3002686
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
 |  zacks.comhttps://www.zacks.com/stock/news/3002605/these-2-medical-stocks-could-beat-earnings-why-they-should-be-on-your-radar?cid=cs-stocknewsapi-ft-fundamental_analysis|zacks_education_earnings_esp-3002605
These 5 Dividend Stocks Are Americas Favorite Companies
 |  247wallst.comhttps://247wallst.com/investing/2026/10/08/these-5-dividend-stocks-are-americas-favorite-companies/
These 5 Dividend Stocks Are Americas Favorite Companies
 |  247wallst.comhttps://247wallst.com/investing/2026/10/08/these-5-dividend-stocks-are-americas-favorite-companies/?utm_source=snapi
Pfizer’s Yield Is Three Times Bigger. Johnson & Johnson’s Dividend Has Something Pfizer Does Not
 |  247wallst.comhttps://247wallst.com/investing/2026/10/08/pfizers-yield-is-three-times-bigger-johnson-johnsons-dividend-has-something-pfizer-does-not/
Pfizer's Yield Is Three Times Bigger. Johnson & Johnson's Dividend Has Something Pfizer Does Not
 |  247wallst.comhttps://247wallst.com/investing/2026/10/08/pfizers-yield-is-three-times-bigger-johnson-johnsons-dividend-has-something-pfizer-does-not/?utm_source=snapi
Congress Asset Management Co. Boosts Stake in Johnson & Johnson $JNJ
October 8 at 3:04 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-congress-asset-management-co-boosts-stake-in-johnson-johnson-jnj-2026-10-08/
Amgen (AMGN) and Johnson & Johnson (JNJ) Catch Jim Cramer’s Eye for Different Reasons
October 7 at 12:16 AM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/amgen-amgn-johnson-johnson-jnj-034526795.html
Pfizer (PFE) Trades Below 10x Earnings. Why Does Johnson & Johnson (JNJ) Command More Than Twice the Multiple?
October 7 at 7:31 PM  |  insidermonkey.comhttps://www.insidermonkey.com/news/pfizer-pfe-trades-below-10x-earnings-why-does-johnson-johnson-jnj-command-more-than-twice-the-multiple-1849276/
Johnson & Johnson (NYSE:JNJ) Pricing Pact Eases Overhang Before Earnings
October 7 at 7:15 PM  |  kalkinemedia.comK
Pfizer (PFE) Trades Below 10x Earnings. Why Does Johnson & Johnson (JNJ) Command More Than Twice the Multiple?
October 7 at 7:15 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/pfizer-pfe-trades-below-10x-211941994.html
Johnson & Johnson (JNJ) Is Becoming a Growth Stock. Does AbbVie (ABBV) Make JNJ Look Expensive?
October 7 at 5:31 PM  |  insidermonkey.comhttps://www.insidermonkey.com/news/johnson-johnson-jnj-is-becoming-a-growth-stock-does-abbvie-abbv-make-jnj-look-expensive-1849275/
Johnson & Johnson (NYSE:JNJ) Stock Jumps 1.4% - Here's What Happened
October 7 at 5:19 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-johnson-johnson-nyse-jnj-stock-jumps-14-heres-what-happened-2026-10-07/
3 ‘Strong Buy’ Dividend Aristocrat Stocks on Analysts’ Watch List
October 7 at 5:11 PM  |  tipranks.comhttps://www.tipranks.com/news/3-strong-buy-dividend-aristocrats-on-analysts-watch-list?utm_source=marketbeat.com&utm_medium=referral
American National Bank & Trust Sells 4,125 Shares of Johnson & Johnson $JNJ
October 7 at 1:03 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-american-national-bank-trust-sells-4125-shares-of-johnson-johnson-jnj-2026-10-07/
24/7 Market News Highlights NeOnc, Revolution Medicines, Moderna, Merck, Johnson & Johnson and Genmab, AbbVie in 2026 Cancer Treatment Advances
October 7 at 9:51 AM  |  quiverquant.comQ
Johnson & Johnson Has Dividend Royalty Status. Does That Make It a Buy?
October 7 at 9:31 AM  |  247wallst.comhttps://247wallst.com/investing/2026/10/07/johnson-johnson-has-dividend-royalty-status-does-that-make-it-a-buy/
Johnson & Johnson Has Dividend Royalty Status. Does That Make It a Buy?
October 7 at 9:30 AM  |  247wallst.comhttps://247wallst.com/investing/2026/10/07/johnson-johnson-has-dividend-royalty-status-does-that-make-it-a-buy/?utm_source=snapi
Johnson & Johnson (NYSE:JNJ) Stock Rating Reaffirmed as Buy by Guggenheim
October 7 at 9:17 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-johnson-johnson-nyse-jnj-stock-rating-reaffirmed-as-buy-by-guggenheim-2026-10-07/
RBC Capital Keeps Their Buy Rating on Johnson & Johnson (JNJ)
October 7 at 9:15 AM  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/JNJ/pressreleases/5002288/rbc-capital-keeps-their-buy-rating-on-johnson-johnson-jnj/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Micron, Coherent and Tower Semiconductor: 3 Stocks Built on AI's Bottlenecks
NVIDIA Just Named AI's Next Bottleneck—And These 3 Stocks Sit Right In It
By Bridget Bennett | September 20, 2026
A Tesla concept vehicle with illuminated front light bar drives on a road against a city skyline at dusk.
Tesla’s Robotaxi Launch Wasn’t the Moment Investors Expected
By Sam Quirke | September 8, 2026
Stacks of coins rising on a desk beside a computer with an upward stock chart, with a blurred city skyline behind.
3 Dividend Kings to Buy While They’re Still Beaten Down
By Thomas Hughes | September 14, 2026
Stacks of US currency and an official document sit on a desk in a government chamber.
3 Stocks to Buy and Hold for Higher Interest Rates
By Thomas Hughes | September 9, 2026
Laboratory workbench with chromatography instrument, pipettes, sample vials, and a notebook, with a production line visible beyond the glass wall.
3 Healthcare Dividend Stocks Offering More Than Just Income
By Chris Markoch | September 30, 2026
Abbott Laboratories stock logo

Abbott Laboratories NYSE:ABT

$97.40 -1.33 (-1.35%)
As of 11:02 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

Johnson & Johnson stock logo

Johnson & Johnson NYSE:JNJ

$252.40 -6.05 (-2.34%)
As of 11:02 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas